Online citations, reference lists, and bibliographies.

TNM Staging Of Foregut (neuro)endocrine Tumors: A Consensus Proposal Including A Grading System

G. Rindi, G. Klöppel, H. Alhman, M. Caplin, A. Couvelard, W. D. de Herder, B. Erikssson, A. Falchetti, M. Falconi, P. Komminoth, M. Körner, J. Lopes, A. McNicol, O. Nilsson, A. Perren, A. Scarpa, J. Scoazec, B. Wiedenmann
Published 2006 · Biology, Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
The need for standards in the management of patients with endocrine tumors of the digestive system prompted the European Neuroendocrine Tumor Society (ENETS) to organize a first Consensus Conference, which was held in Frascati (Rome) and was based on the recently published ENETS guidelines on the diagnosis and treatment of digestive neuroendocrine tumors (NET). Here, we report the tumor–node–metastasis proposal for foregut NETs of the stomach, duodenum, and pancreas that was designed, discussed, and consensually approved at this conference. In addition, we report the proposal for a working formulation for the grading of digestive NETs based on mitotic count and Ki-67 index. This proposal, which needs to be validated, is meant to help clinicians in the stratification, treatment, and follow-up of patients.
This paper references
Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS)
U Plöckinger (2004)
10.1016/S0016-5085(99)70174-5
ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis.
G. Rindi (1999)
10.1007/978-3-642-82982-6
TNM Classification of Malignant Tumours
L. Sobin (1987)
10.1097/01.pas.0000151617.14598.ae
Persistent Hyperinsulinemic Hypoglycemia in 15 Adults With Diffuse Nesidioblastosis: Diagnostic Criteria, Incidence, and Characterization of β-Cell Changes
M. Anlauf (2005)
10.1080/02841860410018502
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms)
K. Öberg (2004)
10.1093/ANNONC/MDJ113
Long-term clinical outcome of somatostatin analogues for treatment of progressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma.
F. Panzuto (2006)
10.1159/000082875
Rapid and Sustained Relief from the Symptoms of Carcinoid Syndrome: Results from an Open 6-Month Study of the 28-Day Prolonged-Release Formulation of Lanreotide
P. Ruszniewski (2004)
Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the
U Plöckinger (2004)
10.1093/ANNONC/MDH216
Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system.
K. Oberg (2004)
10.1097/01.sla.0000129342.67174.67
Updated Population-Based Review of Carcinoid Tumors
M. Maggard (2004)
10.1053/HUPA.2002.129204
Classification of low-grade neuroendocrine tumors of midgut and unknown origin.
S. van Eeden (2002)
10.1159/000200220
Mucosal protective activity of activated aluminum complex.
J. F. Dijoseph (1990)
Recent advances in the pathophysiology and management of inflammatory bowel diseases and digestive endocrine tumors
R T Jensen (1999)
Virchows Arch
(2006)
10.1200/JCO.1998.16.3.1040
Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management.
F. Gibril (1998)
Natural history of digestive endocrine tumors Recent advances in the pathophysiology and management of inflammatory bowel diseases and digestive endocrine tumors
Rt Jensen (1999)
Treatment of metastatic neuroendocrine carcinomas based on WHO classification.
S. Artale (2005)
10.1080/02841860410018584
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms) Part II—Specific NE Tumour Types
K. Öberg (2004)
10.1002/1097-0142(20011015)92:8<2204::AID-CNCR1564>3.0.CO;2-R
Incidence trends and risk factors of carcinoid tumors
K. Hemminki (2001)
10.1159/000051851
Biological and Molecular Aspects of Gastroenteropancreatic Neuroendocrine Tumors
G. Rindi (2000)
Karzinoide Tumoren des Dunndarms
S. Oberndorfer (1907)
10.1046/j.1365-2559.2001.01219.x
Pathology and genetics of tumours of the digestive system
S. Hamilton (2000)
10.1016/S0046-8177(96)90303-2
Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections is an independent predictor for malignancy: a comparative study with proliferating-cell nuclear antigen and progesterone receptor protein immunostaining, mitotic index, and other clinicopathologic variables.
G. Pelosi (1996)
10.1053/J.GASTRO.2005.01.058
Precursor lesions in patients with multiple endocrine neoplasia type 1-associated duodenal gastrinomas.
M. Anlauf (2005)
High resolution allelotype of nonfunctional pancreatic endocrine tumors: identification of two molecular subgroups with clinical implications.
G. Rigaud (2001)
Natural history of digestive endocrine tumors
RT Jensen (1999)
10.1093/ANNONC/MDI258
Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?
E. Bajetta (2005)
10.1159/000199786
Histopathological classification of nonantral gastric endocrine growths in man.
E. Solcia (1988)
10.1007/978-3-642-59655-1
Histological Typing of Endocrine Tumours
E. Solcia (2000)
10.1111/J.1572-0241.1998.00422.X
A Retrospective Analysis of 1570 Appendiceal Carcinoids
A. Sándor (1998)
10.1080/02841860410018575
Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms) Part I—General Overview
K. Öberg (2004)
10.1136/gut.2004.053314
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours
J. Ramage (2005)
10.1159/000080730
From ENET to ENETS: A Long Odyssey in the Land of Small and Rare Tumors
B. Wiedenmann (2004)
10.1677/ERC.1.01017
Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization.
F. Panzuto (2005)
10.1002/ijc.1473
Familial carcinoid tumors and subsequent cancers: A nation‐wide epidemiologic study from Sweden
K. Hemminki (2001)
10.1002/cncr.11105
A 5‐decade analysis of 13,715 carcinoid tumors
I. Modlin (2003)
10.1053/J.GASTRO.2005.03.038
Current status of gastrointestinal carcinoids.
I. Modlin (2005)
10.1200/JCO.2002.10.030
Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.
S. Hochwald (2002)
Pathology and genetics of tumours of endocrine organs
R. DeLellis (2004)



This paper is referenced by
10.5946/ce.2013.46.6.656
Endoscopic Treatment of Duodenal Neuroendocrine Tumors
S. Kim (2013)
10.1016/j.ijsu.2014.03.020
Benign cystic neoplasm and endocrine tumours of the pancreas--when and how to operate--an overview.
Hans Günther Beger (2014)
10.1515/romneu-2016-0054
Diagnostic criteria in invasive pituitary adenomas
Ioana-Maria Moldovan (2016)
10.5603/EP.2017.0015
Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours).
B. Kos-Kudła (2017)
10.1186/s12957-018-1446-y
Treatment options for PNET liver metastases: a systematic review
G. Nigri (2018)
10.16931/1995-5464.20182100-110
Нейроэндокринные опухоли поджелудочной железы: этиология, патогенез, диагностика, современные аспекты лечения
Nikolay Y. Kokhanenko (2018)
Cancer with unknown primary: finding a needle in a hay stack.
F. Giesel (2012)
10.1007/s00268-015-2963-2
CUP Syndrome in Neuroendocrine Neoplasia: Analysis of Risk Factors and Impact of Surgical Intervention
Nehara Begum (2015)
10.3310/hta22490
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
R. Mújica-Mota (2018)
10.1055/s-0032-1327962
[Diagnostics and therapy for neuroendocrine neoplasia of an unknown primary - a plea for open exploration].
Naseema Begum (2014)
10.1007/s13277-013-0850-8
Expression of CK19 and KIT in resectable pancreatic neuroendocrine tumors
Xu Han (2013)
10.1007/s00104-016-0157-6
Endoskopische Therapie gastroduodenaler neuroendokriner Neoplasien
Sebastian Maasberg (2016)
10.3390/nu10121854
Impact of Nutritional Status on Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) Aggressiveness
L. Barrea (2018)
10.1016/j.surg.2018.10.018
Prognostic significance of Chromogranin A in small pancreatic neuroendocrine tumors☆
Mustafa Raoof (2019)
10.5114/pjp.2016.65864
[Tissue heterogeneity contributes to suboptimal precision of WHO 2010 scoring criteria for Ki67 labeling index in a subset of neuroendocrine neoplasms of the pancreas].
Łukasz Liszka (2016)
10.1007/s12020-019-02095-5
Prospective comparison of whole-body MRI with diffusion-weighted and conventional imaging for the follow-up of neuroendocrine tumors
Maximilien Minon (2019)
10.2147/CMAR.S227501
Clinical Analysis of 15 Cases of Gallbladder Neuroendocrine Carcinoma and Comparison with Gallbladder Adenocarcinoma Using a Propensity Score Matching
Shida Yan (2020)
Neuroendokrine Tumoren des Gastrointestinaltraktes Gastrointestinal neuroendocrine tumors
J. Bornschein (2008)
10.1007/978-2-287-72070-3_34
Localisation gastro-intestinale
Eric Baudin (2010)
10.1177/030089161009600530
1. Neuroendocrine Tumors (NETs): Historical Overview and Epidemiology
Kjell E Öberg (2010)
10.1007/s00428-007-0452-1
TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system
G. Rindi (2007)
10.1055/s-0030-1255564
Neuroendocrine tumors of the stomach (gastric carcinoids) are on the rise: small tumors, small problems?
H. Scheruebl (2010)
10.1016/j.ejrad.2015.12.029
Pancreatic neuroendocrine tumour: Correlation of apparent diffusion coefficient or WHO classification with recurrence-free survival.
Mimi Kim (2016)
10.1038/modpathol.2010.127
Pancreatic endocrine tumors
S. Asa (2011)
10.1007/s00292-010-1341-y
TNM 2010
C. Wittekind (2010)
10.2967/jnumed.116.178095
Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors
E. Panagiotidis (2017)
10.1016/j.ejrad.2012.01.032
Pancreatic neuroendocrine tumor: added value of fusion of T2-weighted imaging and high b-value diffusion-weighted imaging for tumor detection.
R. Brenner (2012)
10.1002/cncr.27716
Gastroenteric neuroendocrine neoplasms classification: Comparison of prognostic models
Anna Dolcetta-Capuzzo (2013)
10.3390/ijms18010143
Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future
A. Ohmoto (2017)
10.1002/cam4.1336
Assessment of the American Joint Commission on Cancer 8th Edition Staging System for Patients with Pancreatic Neuroendocrine Tumors: A Surveillance, Epidemiology, and End Results analysis
Xiaogang Li (2018)
Neuroendocrine liver metastasis in gastric mixed adenoneuroendocrine carcinoma with trilineage cell differentiation: a case report.
Wenjin Zhang (2014)
Thrombin generation, tissue factor microvesicles and the endothelium in multiple myeloma and pancreatic cancer during treatment
M. A. Adesanya (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar